CORRESP Filing
CytomX Therapeutics, Inc.
Date: Aug. 14, 2025 · CIK: 0001501989 · Accession: 0001193125-25-180756
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289365
Letter
Re: CytomX Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-289365) To the addressee set forth above: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of CytomX Therapeutics, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on August 18, 2025, or as soon as practicable thereafter. Thank you for your assistance in this matter.
CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 August 14, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Chris Edwards
Very truly yours,
CytomX Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 August 14, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Chris Edwards Re: CytomX Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-289365) To the addressee set forth above: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of CytomX Therapeutics, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on August 18, 2025, or as soon as practicable thereafter. Thank you for your assistance in this matter. Very truly yours, CytomX Therapeutics, Inc. By: /s/ Christopher W. Ogden Christopher W. Ogden Chief Financial Officer CC: Sean A. McCarthy, CytomX Therapeutics, Inc. Mark V. Roeder, Latham & Watkins LLP John C. Williams, Latham & Watkins LLP